Orsini Partners with Vertex to Launch CASGEVY Gene Therapy
Orsini Now Distributing CASGEVY Gene-Editing Therapy
Orsini has been appointed by Vertex Pharmaceuticals Incorporated to distribute CASGEVY, a groundbreaking gene-editing therapy known as exagamglogene autotemcel. This innovative treatment utilizes the CRISPR/Cas9 technology to address serious conditions like sickle cell disease (SCD) and transfusion-dependent ?-thalassemia (TDT). CASGEVY is designed for patients aged 12 and above experiencing recurrent vaso-occlusive crises related to SCD or those who are reliant on frequent blood transfusions due to TDT.
Commitment to Gene Therapy
Brandon Tom, CEO of Orsini, expressed enthusiasm about this new partnership, stating, "With our Cell and Gene Therapy Center of Excellence established over seven years ago, Orsini is well-positioned to partner with Vertex to distribute CASGEVY." This collaboration aims to enhance access to life-changing therapies that can significantly alter the lives of patients suffering from these debilitating conditions.
About Orsini's Services
Orsini has been at the forefront of providing comprehensive and compassionate healthcare for over three decades. Founded in 1987, the company specializes in managing rare diseases and implementing innovative gene therapies. By establishing partnerships with biopharma innovators, healthcare providers, and payors, Orsini is committed to supporting patients and families in navigating the complexities of accessing advanced treatments.
Through its integrated pharmacy solutions that include pharmacy distribution, clinical management, and home infusion services, Orsini simplifies the process for patients, ensuring that they receive the best possible care. The dedicated therapy care teams are highly trained, delivering personalized attention to guarantee that No Patient is Left Behind™.
Quality and Accreditation
Orsini Specialty Pharmacy holds various esteemed accreditations from organizations such as the Accreditation Commission for Health Care (ACHC), The Joint Commission, URAC, and NABP. The pharmacy has received URAC's designation as a Rare Disease Pharmacy Center of Excellence and notable distinctions for its commitment to rare diseases and orphan drugs from ACHC. These accolades reflect Orsini's dedication to quality and excellence in patient care.
Contact Orsini for More Information
For those seeking more information about CASGEVY or other services, Orsini invites inquiries through their main contact number. Interested parties can reach Orsini by calling 847-734-7373 ext. 505. Further details can also be found by exploring their official website.
Frequently Asked Questions
What is CASGEVY?
CASGEVY is a CRISPR/Cas9 gene-edited cell therapy approved for treating patients aged 12 years and older with sickle cell disease and transfusion-dependent ?-thalassemia.
Who is distributing CASGEVY?
Orsini has been chosen to distribute CASGEVY in partnership with Vertex Pharmaceuticals.
What conditions does CASGEVY treat?
CASGEVY is designed to treat sickle cell disease and transfusion-dependent ?-thalassemia in eligible patients.
How long has Orsini been in operation?
Orsini has been providing healthcare services since 1987, focusing on rare diseases and gene therapies.
How can I contact Orsini for more information?
Contact Orsini at 847-734-7373 ext. 505 for inquiries related to their services or CASGEVY.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
